Pubertal androgen therapy in boys

Pediatric Endocrinology Reviews

Volumn 2, Issue 3, 2005, Pages 383-390

  Rogol, Alan D ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE   (United States)

Author keywords

Body composition; Constitutional delay of growth and puberty; Human chorionic gonadotropin; Hypogonadism; Puberty; Testosterone

Indexed keywords

ANDROGEN; CHORIONIC GONADOTROPIN; FLUOXYMESTERONE; FOLLITROPIN; LUTEINIZING HORMONE; METHYLTESTOSTERONE; TESTODERM TTS; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE CIPIONATE; TESTOSTERONE DECANOATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ADOLESCENCE; ANDROGEN THERAPY; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BONE AGE; CHILD DEVELOPMENT; CLINICAL TRIAL; CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY; DELAYED PUBERTY; DIFFERENTIAL DIAGNOSIS; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG SYNTHESIS; DRY SKIN; ESTRADIOL BLOOD LEVEL; GEL; GROWTH ACCELERATION; GROWTH RATE; GROWTH RETARDATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADISM; IMPLANTATION; INJECTION; LABORATORY TEST; LEAN BODY WEIGHT; LIVER TOXICITY; LONG TERM CARE; MUSCLE MASS; PHYSICAL DEVELOPMENT; REVIEW; SEX DIFFERENTIATION; SEXUAL DEVELOPMENT; SEXUAL MATURATION; SIDE EFFECT; SKIN IRRITATION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ANDROGENS; BODY COMPOSITION; BODY HEIGHT; CHILD; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PUBERTY, DELAYED;

EID: 16344365270     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Veldhuis JD, Roemmich JN, Rogol AD. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females-a general clinical research center-based study. J Clin Endocrinol Metab 2000;85:2385-2394
2. Wang C, Swerdloff RS. Androgen pharmacology and delivery systems. In: Bagatell CJ, Bremner WJ, eds. Androgens in Health and Disease. Totowa, NJ: Humana Press, 2003;141-153
3. Butler GE, Sellar, RE, Walker RF, Hendry M, Kelnar CJ, Wu FC. Oral testosterone undecanoate in the management of delayed puberty in boys: pharmacokinetics and effects on sexual maturation and growth. J Clin Endocrinol Metab 1992;75:37-44
4. Brown DC, Butler GE, Kelnar CJ, Wu FC. A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys. Arch Dis Child 1995;73:131-135
5. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FCW. Testosterone replacement therapy: current trends and future directions. Hum Reprodn Update 2004;10:409-419
6. rd edition). Nieschlag E and Behre HM (Eds.), Cambridge University Press, Cambridge, UK (2004):405-444
7. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51:1335-1339
8. Bhasin S, Swerdloff RS, Steiner B, Peterson MA, Meridores T, Galmirini M, Pandian MR, Goldberg R, Berman N. A biodegradable testosterone microsphere formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992;74:75-83
9. Von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002;23:419-425
10. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992;75:1204-1210
11. Handelsman DJ, Mackey MA, Howe C, Turner L, Conway AJ. Analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol 1997;47:311-316
12. Kelleher S, Howe C, Conway AJ, Handelsman DJ. Testosterone release rate and duration of testosterone pellet implants. Clin Endocrinol 2004;60:420428
13. Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986;2:943-946
14. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajarman L Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J Clin Endocrinol Metab 1996;81:1832-1840
15. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-3478
16. Nieschlag E, Behre HM: Clinical uses of testosterone in hypogonadism and other conditions. In: Testosterone: Action, Deficiency, Substitution (3rd edition). Nieschlag E and Behre HM (Eds.), Cambridge University Press, Cambridge, UK (2004): 375-403
17. Crowne EC, Shalet SM, Wallace WBH, Eminson DM, Price DA: Final height in boys with untreated constitutional delay in growth and puberty. Arch Dis Child 1990;65:1109-1112
18. Gross RT, Duke PM. The effect of early versus late physical maturation on adolescent behavior. Pediatr Clin N Amer 1980;27:71-77
19. Duke PM, Carlsmith JM, Jennings D, Martin JA, Dombusch RT, Cross RT, Siegel-Gorelick B. Educational correlates of early and late sexual maturation in adolescence. J Pediatr 1982;100:633-637
20. Degros V, Cortet-Rudelli C, Soudan B, Dewailly D. The human chorionic gonadotropin test is more powerful than the gonadotropin-releasing hormone agonist test to discriminate male isolated hypogonadotropic hypogonadism form constitutional delayed puberty. Eur J Endocrinol 2004; 149:23-29
21. Schopohl J, Eversmann TH, Mehltretter G, Werder K, Zumbusch R. Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertil Steril 1991;56:1143-1150
22. Barrio R, De Luis D, Alonso M, Lamas A, Moreno JC. Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. Fertil Steril 1999;71:244-248
23. Rosenfeld RG, Northcraft GB, Hintz RL. A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics 1987;69:681-687
24. Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988;319:1563-1567
25. Buyukgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995;44 (suppl) 3:32-34
26. Bergada I, Bergada C. Long-term treatment with low dose testosterone in constitutional delay of growth and puberty: effect on bone age maturation and pubertal progression. J Pediatr Endocrinol Metab 1995;8:117-122
27. Kelly BP, Patersin WF, Donaldson MK. Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone, 125 mg per month for 3 months. Clin Endocrinol 2003;58:267-272
28. Arrigo T, Cisteron M, DeLuca F, Saggese G, Messina MF, Pasquino A, DeSanctis V. Final height outcome in both untreated and testosterone-treated boys with constitutional delay of growth and puberty. J Ped Endocrinol Metab 1996;9:511-517